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Background Antilaminin-332 mucous membrane pemphigoid is a chronic sev-
ere pemphigoid disease characterized by autoantibodies to laminin-332. At
present no commercial assay is available to demonstrate antilaminin-332
antibodies, and diagnosis relies on in-house techniques with limited
sensitivities.
Objectives In order to move, keratinocytes cultured in vitro secrete laminin-332 to
attach to the culture dish. In that way, they leave behind a unique footprint trail
of laminin-332. We aimed to develop a sensitive and specific laboratory assay to
determine antilaminin-332 autoantibodies in patient serum based on binding of
patient IgG to these unique footprints.
Methods Normal human keratinocytes were grown on glass coverslips and incu-
bated with patient or control serum for 1 h. The binding of IgG was then inves-
tigated by immunofluorescence. After validating the test for its ability to identify
antilaminin-332 autoantibodies it was converted into a daily available test based
on binding of IgG to dried coverslips that can be stored frozen. The staining pat-
terns of sera from patients with antilaminin-332 pemphigoid were then com-
pared with those of sera from patients with other autoimmune bullous diseases
and normal human sera.
Results IgG of all antilaminin-332 pemphigoid sera (n = 16) bound to laminin-
332 footprints, while all normal human controls (n = 55) were negative. From
the sera of patients with other diseases (n = 72) four sera tested positive. The
footprint assay was also positive for sera that were negative by salt-split skin anal-
ysis, demonstrating that it is a very sensitive technique.
Conclusions The keratinocyte footprint assay is a fast and specific assay to confirm
or rule out the presence of antilaminin-332 autoantibodies.
What’s already known about this topic?
• Antilaminin-332 mucous membrane pemphigoid is a severe form of pemphigoid,
and patients may have an increased risk of malignancies.
• The diagnosis of antilaminin-332 mucous membrane pemphigoid is complicated
by the lack of specific commercial tests for antilaminin-332 antibodies and can be
confirmed only in specialized laboratories.
• Keratinocytes in culture need laminin-332 for adhesion and migration and there-
fore deposit it on the bottom of the culture dish.
What does this study add?
• The keratinocyte footprint assay detects antilaminin-332 autoantibodies in patient
serum using the native laminin-332 produced by cultured keratinocytes.
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What is the translational message?
• The keratinocyte footprint assay is a fast and specific assay to confirm or rule out
the presence of antilaminin-332 autoantibodies.
Mucous membrane pemphigoid (MMP) is a subepidermal
autoimmune blistering disease affecting single or multiple
mucous membranes of the mouth, eyes, nasopharynx,
oropharynx, larynx and anogenital region, with associated skin
involvement in about 30% of cases.1 Formerly termed cicatri-
cial pemphigoid because of the often observed scarring evolu-
tion of the lesions, it is associated with autoantibodies directed
against different antigens located at the basement membrane
zone (BMZ) level.2 These are the intracellular hemidesmosomal
protein BP230, the transmembrane hemidesmosomal proteins
BP180 and integrin a6b4, and laminin-332 (Ln-332). Recent
reviews found that 64–233% of patients with MMP have
autoantibodies against Ln-332, the pathogenicity of which has
been proved by passive transfer in mice and human skin graft
models.1,3–8
Ln-332, formerly known as kalinin, epiligrin, nicein and
laminin-5, is a heterotrimer that consists of the laminin
chains a3, b3 and c2. In a systematic review of 57 studies,
Amber et al. found that for 59 patients the IgG was mostly
directed to the a3 subunit (86%), followed by the c2 sub-
unit (46%) and the b3 subunit (29%).9 Most Ln-332 is
found in the lamina densa and lower lamina lucida under-
neath hemidesmosomes, and is an essential component of
the anchoring filaments that connect the hemidesmosomes
via the adhesion receptors integrin a6b4 and BP180 to the
underlying anchoring fibrils. Similarly, it binds to integrin
a3b1 to bridge focal adhesions and anchoring fibrils.10,11
Genetic absence of the protein leads to severe generalized
junctional epidermolysis bullosa, formerly named type Herl-
itz, a devastating blistering disease fatal in early childhood.12
Apart from its adhesion function Ln-332 also has roles in
cell migration, tissue maturation and wound repair.13,14 Since
1997, 36 anti-Ln-332 cases have been reported in association
with an underlying malignancy.15–31 Early studies reported
that 20–30% of patients had a solid cancer.30,32–34 However,
later studies found no statistically significant differences for
the occurrence of cancer between Ln-332 and non-Ln-332
MMP, and according to Bernard et al. the prevalence rate of
cancer in patients with MMP did not differ from that of the
general population in the same age range in France.3–5
Laboratory diagnosis of anti-Ln-332 is complicated.
Immunofluorescence analysis of a skin biopsy and serum can
give clues but not a definitive diagnosis. The IgG deposition at
the BMZ of a skin biopsy is n-serrated as in pemphigoid diseases,
with antibodies to BP180 or p200. Indirect immunofluores-
cence (IIF) on salt-split skin (SSS) substrate serum shows bind-
ing of IgG to the floor of the blister, as do antibodies to type VII
collagen and p200. The combination of n-serrated deposition
and floor binding thus leaves a diagnosis of either anti-p200 or
anti-Ln-332 pemphigoid. The final diagnosis therefore relies on
the identification of anti-Ln-332 antibodies, and as commercial
tests for this are not available, this is mainly achieved in special-
ized laboratories that have in-house techniques such as
immunoprecipitation, immunoblot, enzyme-linked immuno-
sorbent assay (ELISA) or knockout analysis.3,35,36
As elegantly shown by Frank and Carter, keratinocytes in
culture need Ln-332 to attach to the surface of the culture
dish.14 When migrating, the cells polarize and deposit precur-
sor Ln-332 at the rear of the moving cell. This Ln-332 is left
behind and forms a unique footprint trail. We made use of
this phenomenon to develop a fast and simple serum assay




Sixteen sera from patients with anti-Ln-332 MMP were
included in the study. One (patient 16) had IgG to both Ln-
332 and type VII collagen, and one (patient 12) had Orf-
induced anti-Ln-332 pemphigoid.37,38 IIF on SSS was positive
for dermal IgG binding in 15 cases, and one was judged as
dubious. The final diagnosis was achieved by either immuno-
blot analysis, immunoprecipitation, ELISA or IIF knockout
analysis on type VII collagen-deficient skin and Ln-332-defi-
cient skin (Table 1). We further included 25 sera that also
stained the floor of SSS, 12 sera from patients with epidermol-
ysis bullosa acquisita (EBA) and 13 sera from patients with
anti-p200 pemphigoid. All patients with EBA had u-serrated
IgG deposition on the BMZ on direct immunofluorescence and
dermal staining on SSS IIF. The anti-p200 pemphigoid had
been characterized by immunoblot and IIF on type VII colla-
gen and Ln-332-deficient skin.39
We also included 55 sera from patients who also had
mucosal lesions but who had not been diagnosed with anti-
Ln-332 MMP. These were 30 MMP sera from which 15
labelled the roof of SSS and 15 were negative on SSS, 10 sera
from patients with erosive lichen planes, 11 sera from patients
with paraneoplastic pemphigus, two sera from patients with
erythema exsudativum multiforme, and two sera that stained
both the roof and floor of SSS. Also included were seven sera
from patients with bullous pemphigoid (BP) that stained the
epidermal side of SSS and recognized BP180 and/or BP230 by
immunoblot and/or ELISA. As controls we used 55 normal
human sera.
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Keratinocyte footprint assay on living keratinocyte
substrate
Primary normal human keratinocytes (NHKs) were isolated
from redundant healthy skin obtained from breast reduction
surgery upon written informed consent. NHKs were grown
on 12-mm-diameter glass coverslips (Thermo Fisher Scientific
Inc., Waltham, MA, U.S.A.) in 24-well plates using CnT-Prime
medium (CELLnTEC, Bern, Switzerland) at 37 °C and 5%
CO2. Keratinocytes were seeded at a density of 1 9 10
4 cells
in 500 lL medium in a 19-cm2 well, and after 3 days of cul-
ture the coverslips were incubated with 200 lL 25% serum
in medium for 1 h at 37 °C. The cells were then rinsed three
times with phosphate-buffered saline (PBS), fixed in 2%
formaldehyde for 10 min and stored frozen at 80 °C until
staining. Fixed keratinocytes were stained using 1 : 400
DyLight488-labelled goat antihuman IgG (Thermo Fisher Sci-
entific Inc.) in PBS containing 1% ovalbumin (PBS/OVA).
Keratinocyte footprint assay on air-dried frozen
keratinocyte substrate
NHKs were cultured as described above and after 3 days they
were rinsed three times with PBS and air dried. Cells were
stored frozen at 80 °C until further use. After thawing, the
coverslips were incubated with 1 : 10 serum in PBS/OVA for
1 h at 37 °C. After three washes in PBS, they were stained
with 1 : 400 DyLight488-labelled goat antihuman IgG in
PBS/OVA. Of five sera where the corresponding biopsy had
additional linear IgA BMZ deposition, incubated coverslips
were also stained with 1 : 400 DyLight488-labelled goat anti-
human IgA (Bethyl Laboratories, Montgomery, TX, U.S.A.) in
PBS/OVA.
Immunofluorescence microscopy
To visualize Ln-332 we used monoclonal antibodies for all of
the separate chains: clone 546215 for the a3 subunit, K140
for the b3 subunit and D4B5 for the c2 subunit. Type VII col-
lagen was stained with monoclonal LH72 and BP180/LAD-1
with monoclonal 233. As a secondary step we used Alexa
488-conjugated goat antimouse IgG, and in case of double
staining Alexa 568-conjugated goat antimouse IgG (Thermo
Fisher Scientific Inc.). All coverslips were examined with a
Leica DMRA fluorescence microscope and images were
acquired with a Leica DFC350 FX digital camera (Leica, Wet-
zlar, Germany).
Results
Keratinocytes in culture deposit laminin-332 but not type
VII collagen or BP180
When we stained coverslips with monoclonal antibodies to
Ln-332, binding was observed outside cells in a pattern
described before as migration trails. The same pattern was





binding IB Ln-332 IP Ln-332
ELISA IIF (KO skin)
CancerLn-332 Col7 Col7 Ln-332
1 M 54 IgG 4+, C3c 3+, IgA 2+, IgM 2+ IgG 3+, IgA+ Neg np np  +  Yes
2 F 59 Neg IgG 2+ a3, b3 np np  +  No
3 M 65 IgG 3+, C3c 2+, IgA 1+ IgG 1+ a3 np np np np np No
4 F 86 IgG 3+, C3c 3+, IgA 2+, IgM  IgG 1+ c2 np np  +  No
5a M 27 IgG 2+, C3c 3+ IgG 2+ a3 np +  np np No
6a M 25 IgG 3+,C3c 3+ IgG 2+ a3 np +  np np No
7a F 65 IgG 3+, C3c +/2+ IgG 2+ a3 np + np np np No
8a F 42 IgG 3+, C3c 2+ IgG 2+ a3 np +  np np No
9a M 70 IgG 2+ IgG 1+ a3 + np np np np Yes
10 M 82 IgG 3+, C3c 3+ IgG 3+ a3, b3, c2 np np  np np No
11 M 77 np IgG 2+ a3, b3 np np  +  na
12b F 52 IgG 3+, C3c 3+, IgA 1+ IgG 2+ Neg np np  +  No
13 M 81 np IgG 3+ a3 np np np np np na
14a M 56 IgG 2+, IgA 2+ IgG dubious a3 np + np np np Yes
15 M 63 IgG 3+, C3c 2+ IgG 1+ a3 np np np np np na
16a, c F 64 IgG 3+/4+, C3c +/2+ IgG 3+ a3  + np np np No
BMZ, basement membrane zone; Col7, type VII collagen; DIF, direct immunofluorescence; ELISA, enzyme-linked immunosorbent assay; F,
female; IB, immunoblot; IIF, indirect immunofluorescence; IP, immunoprecipitation; KFA, keratinocyte footprint assay; Ln-332, laminin-
332; M, male; na, not available; Neg, negative; np, not performed; SSS, salt-split skin. IP was performed with radiolabelled human ker-
atinocyte extract.34 IB was performed for all sera on extract of cultured keratinocytes, and for sera of patients 7, 9 and 16 also on human
keratinocyte matrix proteins. ELISA for anti-Col7 was performed with a kit from MBL (Nagoya, Japan) and ELISA for anti-Ln-332 was per-
formed on affinity-purified Ln-332 as described previously.34 a–cDescribed previously by aTerra et al.;34 bvan den Bos et al.38 and cJonkman
et al.37
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obtained for the a3, b3 and c2 chains, showing that each
subunit is available on the coverslip. In contrast, monoclonal
antibodies to the ectodomain of BP180, which is shed in cul-
ture, and type VII collagen did not bind outside cells (Fig. 1).
Therefore, cultured keratinocytes could potentially be used in
a diagnostic assay for anti-Ln-332 MMP.
Keratinocyte footprint assay on a living keratinocyte
substrate
The anti-Ln-332 patient IgG that bound to the coverslips in
the footprint pattern colocalized with the binding of mono-
clonal antibodies to all three laminin chains (Fig. 2 shows
overlap with the c2 subunit). Such footprints were observed
for all anti-Ln-332 pemphigoid sera, including those that were
negative in SSS IIF (Fig. 3a–c). All of the EBA, anti-p200, bul-
lous pemphigoid and normal control group sera did not show
any binding to the Ln-332 footprints, except one (Fig. 3d–l).
The exception was a patient with anti-p200 pemphigoid who
was positive for anti-p200 IgG by immunoblot and whose
serum also bound to Ln-332-deficient skin (not shown). Sera
from six of the seven patients with bullous pemphigoid bound
to the membrane of the cells, in line with the accessibility of
the BP180 ectodomain.
Keratinocyte footprint assay on air-dried frozen
keratinocyte substrate
As living cell incubation is labour intensive we tested whether
patient IgG would also bind to footprints on coverslips that
after 3 days had been air dried and frozen. The results were
identical to the living cell incubation in terms of binding to
laminin (Fig. 4). Tests performed on coverslips stored for 18
months at 30 °C gave the same results as freshly frozen cov-
erslips (not shown). The only difference from living cell
assays was that all sera also bound to the cells, as the cyto-
plasm of dried cells is accessible to IgG and this contains
newly synthesized but not yet secreted antigens. We also
tested the sera of five patients who had, besides IgG, deposi-
tion of IgA along the BMZ, although only one serum sample
bound with IgA to the floor of SSS. Of these five sera the IgA
of two bound to the laminin footprints. Furthermore, we
screened the 55 sera of patients with mucosal lesions that had
not been diagnosed as anti-Ln-332 MMP. We found that in
four cases IgG was present that bound to the Ln-332 on the
coverslip.
Discussion
Specific commercial tests to detect anti-Ln-332 autoantibodies
are lacking, which results in missed or delayed diagnoses of
anti-Ln-332 MMP. Of tests that have been developed in house,
immunoprecipitation using radiolabelled keratinocyte extracts
(a) (b) (c)
Fig 1. Keratinocytes deposit laminin-332 but not type VII collagen or the ectodomain of BP180 on the bottom of the culture dish. Air-dried
coverslips were stained for (a) the laminin-332 b3 subunit, (b) the BP180 ectodomain and (c) type VII collagen. Only laminin-332 is present as




Fig 2. Patient IgG binds to deposited laminin-332. Double staining of
living cells incubated with antilaminin-332 patient IgG for (a) human
IgG and (b) the laminin-332 c2 subunit shows complete
colocalization in the merged panel (c). The white bar represents 50
lm.
© 2019 The Authors. British Journal of Dermatology
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Fig 3. IgG binding patterns after incubation of different types of pemphigoid sera with living keratinocytes. Binding patterns after 1-h incubation
with sera of patients with (a–c) antilaminin-332 mucous membrane pemphigoid, (d–f) epidermolysis bullosa acquisita, (g–i) anti-p200
pemphigoid and (j–l) bullous pemphigoid and (m–o) normal human control sera. The white bar represents 150 lm.
© 2019 The Authors. British Journal of Dermatology
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is the most sensitive and specific, but it is restricted to special-
ized laboratories. It is labour intensive and its high costs and
risks do not make it a practical test. Immunoblot analysis has
a lower and also variable sensitivity due to the amount of Ln-
332 in the substrate and the absence of conformational epi-
topes.35,40,41 A commercial ELISA for anti-Ln-332 IgG is not
available, but a few in-house ELISAs have been developed by
independent laboratories with varying success. The first
reported ELISA for anti-Ln-332 used a recombinant form of
Ln-332. Its sensitivity was 91% but specificity was low as it
was also positive for 40% of tested bullous pemphigoid
sera.42
Extraction of the extracellular matrix that keratinocytes
deposit on the bottom of the culture dish results in a sub-
strate that is extremely rich in Ln-332.43 When this sub-
strate was used in ELISA a high number of false-positives
were again found in the bullous pemphigoid group when
polyclonal secondary antibodies were used, but when a
monoclonal antibody to IgG4 was used as a secondary anti-
body the sensitivity became 91% with a specificity of 98%,
although here also 13% of the bullous pemphigoid patient
sera tested positive. More recently an ELISA based on puri-
fied Ln-332 from SCC25 cells found only 2% positives in





Fig 4. IgG binding patterns after incubation of different types of pemphigoid sera with air-dried coverslips. Binding patterns of sera of patients
with (a–c) antilaminin-332 mucous membrane pemphigoid, (d–f) epidermolysis bullosa acquisita, (g–i) anti-p200 pemphigoid and (j–l) bullous
pemphigoid. The white bar represents 60 lm.
© 2019 The Authors. British Journal of Dermatology
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bullous disease; however, the sensitivity and specificity were
not provided.5
The keratinocyte footprint assay we developed is based on
the exclusive binding of anti-Ln-332 IgG to the deposited
extracellular matrix Ln-332. No deposition of type VII colla-
gen or the shed ectodomain of BP180 was found on the plate,
although it is known that both proteins are secreted in the
medium.44,45 Also, the laminin c1 chain is not deposited on
the culture dish, as reported before.46 In our series, all sera
from patients diagnosed with anti-Ln-332 MMP tested positive
for footprint binding, while all 55 normal human control sera
tested negative. IgG of 24 EBA and anti-p200 pemphigoid
sera, which, as with anti-Ln-322, also bind the floor of SSS,
did not bind to the footprints. For one case that had proven
anti-p200 IgG antibodies we found that the serum also con-
tained antibodies to Ln-332 as it bound to the footprints,
making this case mixed anti-p200 and anti-Ln-332 pem-
phigoid. IgG of six bullous pemphigoid sera bound to living
cells in line with the accessibility of the BP180 ectodomain.
One case that by immunoblot and ELISA only demonstrated
IgG to BP230 did not bind to the cells in accordance with the
cytoplasmic location of BP230 (not shown).
Together these results demonstrate that the specificity of the
assay is probably close to 100%. When we analysed patients
with non-Ln-332 MMP we found no binding for sera from
patients with oral erosive lichen planus or erythema exsuda-
tivum multiforme. One of the 11 cases of paraneoplastic pem-
phigus also demonstrated anti-Ln-332 IgG. A similar case of
paraneoplastic pemphigus with additional anti-Ln-332 IgG has
been described before.47
One of the two sera that stained both the roof and floor of
SSS was also positive for anti-Ln-332. Such cases have been
described before by Hayakawa et al.3 Two of the other 30
MMP sera also contained anti-Ln-332 IgG antibodies. One
serum sample was from a patient who had oral, nasal, pharyn-
geal and laryngeal mucous membranes affected without skin
involvement. A skin biopsy demonstrated BMZ deposition of
IgG and IgA; however, all serology was negative. Based on the
positive keratinocyte footprint assay a final diagnosis of anti-
Ln-332 MMP was made. The other serum sample bound the
roof of SSS and was anti-NC16A ELISA positive; immunoblot-
ting demonstrated both anti-BP180 IgG and IgA antibodies.
The concomitant presence of antibodies to Ln-332 and
BP180 has been described already several times.24,48,49 These
last two patients show that a small percentage of patients with
MMP who are not initially diagnosed with anti-Ln-332 MMP
may have antibodies to Ln-332. Although the titres are below
the detection level of SSS IIF the antibodies might still con-
tribute to the clinical phenotype. However, this has to await a
larger series of patients to compare the clinical details of those
with and without additional anti-Ln-332 antibodies.
The possibility to perform the keratinocyte footprint assay
on freezer-stored coverslips makes it a practical assay that
within a few hours will confirm or rule out anti-Ln-332
MMP. If a biopsy is available, it is possible to discriminate
most cases with IIF SSS floor-binding sera between EBA, anti-
Ln-332 pemphigoid and anti-p200 pemphigoid. In EBA the IgG
BMZ deposition in the biopsy will be u-serrated; if the deposi-
tion in the biopsy is n-serrated then sera with a positive
keratinocyte footprint assay are from patients with anti-Ln-332
pemphigoid and sera that are negative are from patients with
anti-p200 (Fig. 5).
The keratinocyte footprint assay that we report here repre-
sents a simple and reliable assay for routine diagnostics that
rapidly identifies the presence of anti-Ln-332 antibodies. The
keratinocyte footprint assay could be of help for prospective
case–control studies to demonstrate or not the reality of the
association of Ln-332 MMP with cancer.
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